China 2014: What's New?

Submitted by Dr. Brian GM Durie on Thu, 04/17/2014 - 00:00

The IMF Asia Pacific team members just returned from China, where we participated in the annual activities of the IMF's Chinese Myeloma Working Group (CMWG).

Black Swan, Salamanca, and the FDA: Debut of a Highly Sensitive New MRD Test

Submitted by Dr. Brian GM Durie on Thu, 03/27/2014 - 00:00
A significant event in the evolution of the IMF's Black Swan Research Initiative occurred this past weekend in Salamanca, Spain.

Measuring Minimal Residual Disease in Myeloma

Submitted by Dr. Brian GM Durie on Thu, 02/20/2014 - 00:00
A recent editorial in Leukemia authored by doctors Shaji Kumar and Vincent Rajkumar of the Mayo Clinic in Rochester, MN, provides a thoughtful overview of the current status of minimal residual disease (MRD) assessment in myeloma.

Understanding MGUS and Early Myeloma: News and Notes

Submitted by Dr. Brian GM Durie on Thu, 02/06/2014 - 00:00
This week there are several interesting items in the news that help us understand how and why monoclonal gammopathy of undetermined significance (MGUS) occurs, and when it may or may not turn into active myeloma.
 

Can an Aspirin a Day Keep the Doctors Away?

Submitted by Dr. Brian GM Durie on Thu, 01/30/2014 - 00:00
A new study shows that regular aspirin use reduces the risk of myeloma. Researchers from Brigham and Women's Hospital and Harvard University studied 2,395,458 person-years and showed a 39% lower myeloma risk among individuals with a cumulative average of more than 5 adult strength (325 mg) aspirin tablets per week.
 

Pages

more